← Back to Clinical Trials
Recruiting NCT06459024
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Trial Parameters
Condition Acute Myeloid Leukemia, in Relapse
Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Study Type OBSERVATIONAL
Phase N/A
Enrollment 4,000
Sex ALL
Min Age 6 Years
Max Age N/A
Start Date 2024-06-28
Completion 2032-07
Interventions
Registration into the STREAM platform
Brief Summary
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites
Eligibility Criteria
Inclusion Criteria: * Patients with AML diagnosis according to WHO2022 or ICC2022 * Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria * Participant or his/her legal representative is willing and able to give informed consent for participation in the study Exclusion Criteria: * Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.